Stock Performance (Oct 3, 2025) As of midday Oct 3, Humana shares were $272.05, up about +6.01% on the day reuters.com. Yesterday’s close (Oct 2) was $256.62 reuters.com, so HUM has recovered much of last week’s slide. In fact, Oct 1 saw a ~5% drop (on news of scaling back Medicare Advantage plans) finviz.com, but Oct 2’s star rating news spurred a ~3% gain reuters.com. By Friday morning, industry data show HUM stock as one of the S&P 500’s top gainers (+5.6%) reuters.com. Year‑to‑date Humana is roughly flat, trading ~19% below its 52-week high (~$312 in Sept 2025) finviz.com. Recent News Driving HUM Medicare Star Ratings Breakthrough

Key Facts (as of Oct 3, 2025): U.S. markets are open (Fri Oct 3). Peabody Energy (NYSE: BTU) is trading around $31.0 per share (as of ~10:30 AM EDT), up roughly +5.9% on the day marketbeat.com. Trading volume is heavy (20-day avg ~5.4 M shares stockanalysis.com). Market Cap is ≈$3.9 billion stockanalysis.com. Key ratios: trailing P/E ≈28.8, forward P/E ~64 stockanalysis.com (reflecting squeezed near-term earnings); EPS (TTM) ≈$1.10 stockanalysis.com; Revenue ~$4.04 B (TTM) stockanalysis.com. Peabody pays a $0.30 annual dividend (~1.0% yield) stockanalysis.com (last declared $0.075 in Q3’25 investing.com). Financially, Peabody holds net cash (~$192M: $586M cash vs $394M debt stockanalysis.com) and book equity

Stock Performance (Oct 3, 2025) As of this afternoon’s trading on Oct 3, Oscar Health shares are up ~2.8% around $19.81. The stock opened near $19.82 and is trading in a tight range (today’s low ~$19.80, high ~$19.95). Yesterday (Oct 2) it closed at $19.28 (+2.0%), continuing a rebound from late-September lows (it had hit ~$17 in mid-September). Volume so far is modest (~0.2M vs a 3‑month average of ~0.5M). Year-to-date Oscar’s stock is up roughly 30–40% from 2024 lows (last fall it traded under $15), and it has outpaced many traditional insurers on a percentage basis this year nasdaq.com.

Stock Performance & Technical Indicators As of midday Oct 3, 2025, NNNN is trading around $37.9, up about +49% on the day investing.com. (Yesterday’s close was $25.40 investing.com.) After opening ~$26.70, the stock climbed quickly; the day’s low/high range is ~$26.46–$37.89 investing.com. This explosive move follows the prior day’s steep decline (Oct 2 close ~$25.4). Total volume has surged well above its modest norms, reflecting extreme volatility (stockanalysis shows ~24K by mid-morning Oct 3 stockanalysis.com, roughly twice the typical daily volume). Technical indicators remain mixed. The 14-day RSI is ~54.6 (neutral) investing.com. Short-term moving averages signal continued strength: the 5-day MA is ~$27.2 (a strong buy signal

Mesoblast’s stock has surged recently on the Ryoncil news. At the Oct 2 close it stood at $17.02 – up +4.6% on the day and roughly +8% from two weeks prior stockinvest.us marketbeat.com. This rally follows last week’s announcements: on Sept 26 the company announced its therapies are U.S.-origin and exempt from tariffs nasdaq.com, and on Oct 2 it disclosed that CMS has made the HCPCS J‐Code for Ryoncil (J3402) permanent starting Oct 1 stocktitan.net. CEO Silviu Itescu called the new J-code “a critical element for successful commercialization of rare disease products, ensuring more efficient billing and enabling timely access

Stock Price & Trading Activity (Oct 3, 2025) On Thursday, Oct. 2, DGNX jumped to $15.80 (close) from $14.56 the day prior stockanalysis.com. Thursday’s intraday range was roughly $14.88–$16.64, and volume hit 671,462 shares stockanalysis.com (versus ~348K on Oct. 1 stockanalysis.com). The stock has formed a broad trading range in recent weeks (the 52-week high is $19.54 on Sept. 22, up from a low near $0.06 last year benzinga.com), so yesterday’s gain brought DGNX back toward its recent highs. As of this morning (Oct. 3 open), the stock is trading around $15.75–$15.80, roughly flat with yesterday’s close (technical forecasts had predicted an opening ~+$0.17% at